Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

Fluticasone is a potent corticosteroid widely used in the management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. As an anti-inflammatory agent, fluticasone works by reducing airway inflammation and improving airflow, providing significant relief from symptoms such as wheezing, shortness of breath, and nasal congestion. Given its role in treating chronic conditions, understanding the pharmacokinetics of fluticasone is essential to optimize its clinical efficacy and minimize the risk of side effects. Pharmacokinetics refers to the study of the absorption, distribution, metabolism, and excretion (ADME) of a drug in the body. For fluticasone, these processes determine its effectiveness and safety. When administered via inhalation or intranasal spray, fluticasone is primarily targeted to the lungs or nasal passages, where its anti-inflammatory effects are most needed. These routes of administration ensure that the drug exerts a local effect while minimizing systemic exposure and the risk of systemic corticosteroid-related side effects [1]. However, systemic absorption of fluticasone does occur to a small extent, especially with oral formulations or when large doses are used.

Methodology

The pharmacokinetics of Fluticasone, a synthetic corticosteroid used to treat asthma, rhinitis, and other respiratory conditions, involves understanding its absorption, distribution, metabolism, and excretion (ADME). The methodology of studying Fluticasone’s pharmacokinetics combines experimental data, mathematical modeling, and clinical observations to determine how the drug behaves in the body.

Absorption of fluticasone

Fluticasone is administered via different routes, including inhalation, intranasal spray, and oral dosage forms, with inhalation being the most common method for treating asthma and COPD. The absorption of fluticasone varies based on the route of administration.

When inhaled, fluticasone is deposited directly into the lungs, where it exerts its primary action. However, only a small fraction of the inhaled dose is actually absorbed into the systemic circulation [2-4]. This is because most of the drug is deposited in the lungs and localizes its effect, while a smaller portion is swallowed and subsequently absorbed through the gastrointestinal tract. The oral bioavailability of inhaled fluticasone is low (approximately 1–2%) due to extensive first-pass metabolism in the liver.

For intranasal administration, fluticasone is used to treat allergic rhinitis and nasal polyps. Similar to inhalation, fluticasone undergoes limited systemic absorption when administered nasally. The absorption from the nasal cavity is also low, and much of the drug remains localized within the nasal passages, where it exerts its anti-inflammatory effects.

When taken orally in higher doses (often as part of combination therapy for severe asthma or COPD), fluticasone is absorbed through the gastrointestinal tract but undergoes significant first-pass metabolism in the liver, resulting in low systemic availability [5].

Distribution of fluticasone

Once fluticasone enters the bloodstream, it is widely distributed throughout the body. The drug is highly protein-bound to plasma proteins, particularly albumin, which restricts its free fraction in the bloodstream. Approximately 91% of fluticasone is bound to plasma proteins, leaving only a small amount available to exert pharmacological effects.

Fluticasone has a relatively low volume of distribution (Vd), suggesting that it remains predominantly within the central compartments, such as the plasma and highly perfused tissues, rather than penetrating deeply into peripheral tissues [6,7]. However, the drug does cross biological barriers, including the blood-brain barrier and placental barrier, albeit in small amounts. This is important in cases where fluticasone might be used in pregnant or breastfeeding individuals, although systemic concentrations remain low due to its local action and poor systemic bioavailability.

Inhaled fluticasone primarily accumulates in the lungs, where its local anti-inflammatory effects occur, and this allows the drug to exert its therapeutic effects with minimal systemic side effects.

Metabolism of fluticasone

Fluticasone undergoes extensive first-pass metabolism in the liver, which significantly reduces its systemic bioavailability. This metabolism is primarily mediated by the cytochrome P450 (CYP) enzymes, specifically CYP3A4. In the liver, fluticasone is metabolized into various inactive metabolites, which are then excreted through the urine [8].

Fluticasone has a high first-pass metabolism after oral or inhaled administration, contributing to its low bioavailability. The major metabolite of fluticasone, 16α-hydroxyfluticasone, is biologically inactive and does not contribute to the drug’s therapeutic effects [9].

For oral formulations, the metabolism of fluticasone leads to a significant reduction in systemic exposure, limiting the likelihood of systemic side effects. However, this extensive metabolism may be affected by factors such as liver dysfunction or the concurrent use of drugs that inhibit or induce CYP3A4, potentially altering fluticasone’s metabolism and efficacy.

Excretion of fluticasone

Fluticasone is primarily eliminated from the body via renal excretion. Following hepatic metabolism, the drug is excreted in the urine as inactive metabolites. Only a very small fraction of the drug is eliminated unchanged in the urine, as the majority is metabolized in the liver before excretion. The half-life (T½) of fluticasone varies based on the route of administration [10]. When administered via inhalation, fluticasone has a half-life of approximately 6 hours, while the half-life can be slightly longer for oral or nasal formulations.

Fluticasone’s long elimination half-life contributes to its sustained anti-inflammatory effects, even after the drug has been cleared from the systemic circulation. This feature is beneficial for patients, as it allows for less frequent dosing schedules.

Conclusion

Fluticasone's pharmacokinetics are characterized by its low systemic absorption, extensive first-pass metabolism, and localized action when administered via inhalation or intranasal routes. These properties contribute to its efficacy in treating conditions like asthma and allergic rhinitis while minimizing the risk of systemic side effects. Understanding the ADME processes of fluticasone is critical in optimizing treatment regimens for individual patients, particularly when considering factors like liver function, drug interactions, and the method of administration. Overall, fluticasone remains an effective and relatively safe corticosteroid for respiratory conditions when used appropriately.

1. Kelsen J, Baldassano RN (2008) Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis 14: 9-11.

Indexed at, Google Scholar, Crossref

2. Sauer CG, Kugathasan S (2009) Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol Clin North Am 38: 611-628.

Indexed at, Google Scholar, Crossref

3. Bradley GM, Oliva-Hemker M (2012) Pediatric ulcerative colitis: current treatment approaches including role of infliximab. Biologics 6: 125-134.

Indexed at, Google Scholar, Crossref

4. Kelsen J, Gupta K, Grossman A, Mamula P, Baldassano R (2011) Infliximab therapy in pediatric patients 7 years of age and younger: O‐10. J Pediatr Gastroenterol Nutr 17: 5.

Indexed at, Google Scholar, Crossref

5. Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, et al. (2012) Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 10: 391-399.

Indexed at, Google Scholar, Crossref

6. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, et al. (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterol 132: 863-873.

Indexed at, Google Scholar, Crossref

7. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476.

Indexed at, Google Scholar, Crossref

8. Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625-1629.

Indexed at, Google Scholar, Crossref

9. Turner D, Otley AR, Mack D, Hyams J, De Bruijne J, et al. (2007) Development, validation and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterol 133: 423-432.

Indexed at, Google Scholar, Crossref

10. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, et al. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2: 542-553.

Indexed at, Google Scholar, Crossref